Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, published by W B SAUNDERS CO-ELSEVIER INC, is a premier journal dedicated to advancing the fields of hematology and oncology. With its ISSN 0889-8588 and E-ISSN 1558-1977, this esteemed publication has been a cornerstone of clinical scholarship since its inception in 1987, providing comprehensive annual updates that bridge the gap between research and clinical practice. Known for its rigorous editorial standards and impactful contributions, the journal holds a respectable Q2 quartile classification in both hematology and oncology as of 2023, ranking it in the 50th percentile among its peers. Although it is not an open-access journal, the content is accessible to institutions and professionals worldwide. As the scope of the journal expands through 2024, it continues to attract an audience of researchers, healthcare professionals, and students who seek to stay informed on the latest advancements, treatment modalities, and groundbreaking studies in the fields of hematology and oncology.

Cancer Control is a prominent open-access journal published by SAGE Publications Inc, dedicated to advancing the field of oncology, hematology, and general medicine since its inception in 1995. With a focus on disseminating high-quality research, the journal contributes significantly to the knowledge base surrounding cancer prevention, treatment, and survivorship, making it a vital resource for researchers, healthcare professionals, and students alike. The journal currently holds a commendable position in the academic landscape, ranking in the Q2 category for both Hematology and Oncology, highlighting its impact and scholarly relevance. Available in an open-access format since 2018, Cancer Control ensures that critical findings are accessible to a broad audience, promoting collaboration and innovation in cancer-related research. Whether you're interested in the latest clinical trials, epidemiological studies, or public health initiatives, this journal serves as a key platform for sharing significant developments in cancer care and control.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

The Journal of Cancer Epidemiology, published by HINDAWI LTD, is a premier open access journal that has been disseminating vital research findings since 2008. With ISSN 1687-8558 and E-ISSN 1687-8566, this journal is dedicated to enhancing our understanding of cancer's epidemiological factors, thereby fostering advancements in public health, genetics, and environmental health. The journal's current quartile ranking places it in Q3 for Epidemiology and Public Health, as well as Q4 for Genetics, reflecting its growing influence in these fields. As of 2023, it holds respectable Scopus rankings, including a rank of #73 in Epidemiology, positioning it within the 51st percentile. Based in the United States with an address in London, this journal represents a crucial platform for researchers, professionals, and students eager to contribute to the global fight against cancer. For those passionate about uncovering insights into cancer risk factors and trends, the Journal of Cancer Epidemiology offers a comprehensive repository of high-quality research accessible to all.

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Cancer Epidemiology Biomarkers & Prevention is a premier journal published by the American Association for Cancer Research, dedicated to advancing the understanding of cancer epidemiology, biomarkers, and preventive strategies. With an impressive impact factor that places it in the Q1 quartile across three critical categories — Epidemiology, Medicine, and Oncology — the journal stands as a vital resource for researchers and healthcare professionals seeking to explore novel insights in cancer prevention and control. The journal's rigorous selection process ensures the high quality of published research, making it a trusted source for the latest findings and methodologies in the fight against cancer. Although it currently does not support open access, the journal's comprehensive articles, spanning from its inception in 1983 to the present, facilitate significant advancements in the field. Located in Philadelphia, PA, this journal not only serves as a platform for dissemination but also stimulates vital discussions among the oncology community, ensuring that significant translational research reaches its audience effectively.